Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Effector Therapeutics Inc (EFTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2024: EFTR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -78.85% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.00M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 38305 | Beta 0.54 | 52 Weeks Range 0.00 - 4.10 | Updated Date 04/2/2025 |
52 Weeks Range 0.00 - 4.10 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -83.33% | Return on Equity (TTM) -946.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5134060 | Price to Sales(TTM) 69.65 |
Enterprise Value -5134060 | Price to Sales(TTM) 69.65 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.41 | Shares Outstanding 4704410 | Shares Floating 4657224 |
Shares Outstanding 4704410 | Shares Floating 4657224 | ||
Percent Insiders 2.91 | Percent Institutions 3.5 |
Analyst Ratings
Rating 4.5 | Target Price 6.85 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Effector Therapeutics Inc
Company Overview
History and Background
Effector Therapeutics, Inc. (EFTR) is a clinical-stage biopharmaceutical company founded in 2012. It focuses on developing selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company is based in San Diego, California.
Core Business Areas
- Oncology Drug Development: Effector Therapeutics focuses on the discovery and development of small molecule selective translation regulator inhibitors (STRIs) for cancer treatment.
Leadership and Structure
Steve Worland is the President and CEO. The company has a board of directors and a management team overseeing research and development, clinical trials, and corporate operations.
Top Products and Market Share
Key Offerings
- Tomivosertib: Tomivosertib (eFT508) is the company's lead clinical candidate. It's an inhibitor of 4E kinase, targeting the MNK pathway. It is being evaluated in clinical trials for various cancers. There is no current market share as it is still in clinical trials and not approved for marketing. Competitors include other companies developing kinase inhibitors for oncology.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investment in oncology drug development. There is a high demand for novel cancer therapies.
Positioning
Effector Therapeutics is positioned as a clinical-stage biopharmaceutical company focused on a novel approach to cancer treatment by targeting translation regulation. Its competitive advantage lies in its proprietary STRI platform and the potential of tomivosertib to address unmet needs in cancer therapy. The company is very small relative to the overall market size
Total Addressable Market (TAM)
The global oncology market is estimated at hundreds of billions of dollars. Effector Therapeutics targets specific cancer subtypes within this broader market, and therefore only addresses a small segment of the total market.
Upturn SWOT Analysis
Strengths
- Novel STRI platform
- Lead clinical candidate (tomivosertib)
- Experienced management team
- Focus on a high-need area (oncology)
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- No currently marketed products
- High risk of clinical trial failure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of STRI platform to other indications
- FDA approval for tomivosertib
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- Large pharma companies involved in oncology development and smaller biotechs targeting similar pathways (specific stock symbols not provided due to breadth and shifting competitive landscape).
Competitive Landscape
Effector Therapeutics faces intense competition in the oncology market. Its advantage lies in its novel approach, but it is smaller and has fewer resources than many of its competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by advances in its clinical programs. As a development-stage company, revenue growth is limited.
Future Projections: Future growth depends on the success of its clinical trials and potential partnerships. Analyst estimates should be consulted for projections.
Recent Initiatives: Recent initiatives include ongoing clinical trials for tomivosertib and exploration of new indications for its STRI platform.
Summary
Effector Therapeutics is a clinical-stage company with a novel technology focused on cancer therapeutics. The company's success is heavily dependent on its clinical trial results. Its strengths lie in its innovative STRI platform, but weaknesses include limited financial resources. It is still an early-stage and high-risk/high-reward company to invest in.
Similar Companies
Sources and Disclaimers
Data Sources:
- Effector Therapeutics Inc. SEC Filings (10-K, 10-Q)
- Company Website
- Financial News Outlets
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is difficult to assess precisely at the clinical trial phase and has been estimated to be 0%.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Effector Therapeutics Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2021-08-26 | CEO, President, Treasurer &Secretary, and Director Mr. Craig R. Jalbert CIRA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://effector.com |
Full time employees 14 | Website https://effector.com | ||
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.